Streamlining ANDA Review is Key

The U.S. Food and Drug Administration (FDA) held the Generic Drug Forum (GDF) on April 22-23, 2026, addressing the review, manufacturing, and quality aspects of Abbreviated New Drug Applications (ANDAs). This event focuses on regulatory education to resolve issues repeatedly encountered by applicants, such as bioequivalence (BE), major deficiencies, patent/exclusivity, and priority review, rather than announcing approvals of individual drugs or changes in clinical stages. GDUFA III, effective from October 2022 to September 2027, aims to review and act on 90% of standard ANDAs within 10 months. Improved submission quality will reduce the number of requests for additional information and review cycles, thereby improving predictability in launch timelines.

Lowering Technical Barriers for Complex Generics

The FDA focused on complex products that are more difficult to demonstrate equivalence for compared to conventional oral solid dosage forms, including non-oral complex formulations, drug-device combination products, ophthalmic suspensions, and oligonucleotides. Product-Specific Guidelines (PSGs) and pre-ANDA meetings are tools to help applicants align on the reference drug, study design, and quality attributes early in development. This contrasts with the development of new drugs based on Phase 1, 2, and 3 clinical trials, as ANDAs rely on the safety and efficacy of approved reference drugs while demonstrating bioequivalence and manufacturing quality. For companies like Teva Pharmaceutical Industries (TEVA), Sandoz Group AG (SDZNY), and Viatris Inc. (VTRS) with established complex formulation development and manufacturing capabilities, this presents an opportunity to reduce rework costs, but for companies with weaker analytical and manufacturing capabilities, it can be a barrier to entry.

Quality and Safety Data Differentiate Competitors

The forum addressed the Inactive Ingredient Database (IID), Maximum Daily Dose (MDD), Drug Master File (DMF) for raw materials, data integrity, and Quality Management Maturity (QMM). It also included nitrosamine risk assessment, extractables and leachables, and lyophilization and liquid dosage form defects, emphasizing a holistic quality system rather than mere paperwork. QMM was presented as a policy direction for evaluating supply reliability and continuous quality improvement capabilities, rather than a confirmed incentive program in this event. Therefore, inadequate manufacturing readiness and data reliability can lead to increased review delays and requests for additional information, regardless of the 10-month target.

Impacts Launch Speed in Major Markets

The global generic drug market is projected to grow from $470.39 billion in 2026 to $729.05 billion in 2034, with a compound annual growth rate of 5.63%. Competition is not just about individual brands or ingredients, but about multiple ANDAs targeting off-patent originator drugs and portfolio competition among companies like Teva, Sandoz, Viatris, Aurobindo Pharma, and Lupin. As the use of PSGs and pre-meetings increases, the entry of first or early generics for complex formulations will be accelerated, improving drug pricing and patient access. However, the clarification of standards reinforces a structure in which market share is concentrated in companies that invest in regulatory science, analytical technology, and manufacturing quality, rather than those that compete solely on price.